What is WAVE Life Sciences?
WAVE Life Sciences is dedicated to advancing genetic medicines through its proprietary PRISM platform, which enables the precise design, optimization, and production of stereopure oligonucleotides. The company is targeting a broad spectrum of genetically defined diseases, aiming to deliver best-in-class therapies. Its focus on a robust discovery and development engine positions it as a significant player in the biopharmaceutical sector, seeking to translate scientific innovation into tangible patient benefits.
How much funding has WAVE Life Sciences raised?
WAVE Life Sciences has raised a total of $451.3M across 5 funding rounds:
Multiple Rounds
$196M
Stock Offering
$93.5M
Stock Offering
$161.8M
Series A (2015): $18M with participation from Kagoshima Shinsangyo Sosei Investment, RA Capital Management, and SNBL Ltd
Series B (2015): $66M led by Clough Capital Partners, Jennison Associates, Redmile Group, Foresite Capital, Fidelity Management Research Company, New Leaf Venture Partners, Kagoshima Shinsangyo Sosei Investment, RA Capital Management, and Cormorant Asset Management
Stock Issuance/Offering (2015): $112M supported by Undisclosed
Stock Issuance/Offering (2017): $93.5M featuring Undisclosed
Stock Issuance/Offering (2019): $161.8M backed by Undisclosed
Key Investors in WAVE Life Sciences
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. Their internal think tank, TechAtlas, analyzes scientific and clinical data to support their investment strategies.
Jennison Associates
Founded in 1969, Jennison Associates offers a range of equity and fixed income investment services across distribution channels. Jennison Associates is headquartered in New York, NY.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
What's next for WAVE Life Sciences?
With a significant capital infusion, WAVE Life Sciences is poised to accelerate its clinical development pipeline and further enhance its PRISM platform. The company's strategic focus on addressing genetically defined diseases suggests a continued emphasis on precision medicine. Future endeavors will likely involve expanding its therapeutic modalities and advancing its lead programs through critical clinical milestones, potentially leading to new therapeutic options for patients with unmet medical needs.
See full WAVE Life Sciences company page
